Healthcare
Sanofi and Regeneron made a deal with pharmacy benefits manager Express Scripts for their Praluent, making it the exclusive PCSK9 inhibitor on their national formulary, essentially locking Amgen’s Repatha out of that market segment.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
There is almost always exciting research going on every day. Here are just a few that caught BioSpace’s attention this week.
The retail price of prescription drugs is a concern for many people in the United States. Now CVS is attempting to disrupt the retail end of things with a new savings finder tool.
Another major healthcare buyout may be on the horizon. According to reports, Walmart may be in talks to buy health insurer Humana.
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy.
Shanghai’s C-Bridge Capital plans to raise $650M for its third healthcare PE fund, just six months after closing its second fund with $400M.
The 55-to-43 vote for Azar ushers in his return to the government’s largest domestic agency, where he held senior roles previously.
The 2016 U.S. presidential election was marked by aggressive and often shrill attacks on the biopharma industry over drug pricing.
Nestle submitted the highest offer and Merck was likely to select a winner during the first quarter, but might also choose not to sell the assets after all.
PRESS RELEASES